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Background Oral factor Xa inhibitors are increasingly used for anticoagulation but there is no approved reversal agent. Prothrombin complex concentrate (PCC) for management of Xa-inhibitor-associated bleeding has been described in a small case series [1] . The dose used was 2100-4800 units. The duration of bleeding after punch biopsy in volunteers treated with edoxaban was shortened by PCC in a dose-dependent manner [2] Methods
Design
Observational multicenter cohort study performed at hospitals in Canada where PCC was readily available and where a hospital protocol existed that suggested or recommended the use of PCC for reversal of dabigatran-associated bleeding. The study was originally planned for 35 patients but has now been expanded to 60 patients.
Study patients
Acute and active major bleeding (ISTH criteria 
Study procedures
Treating physician requests PCC (Octaplex, Octapharma® or Beriplex® P/N, CSL Behring) from Transfusion medicine. Study staff is notified that PCC was given. Consent obtained for data collection and 30 day follow-up. Treating physician rates effectiveness using an Assessment Guide modified from Sarode et al [3] . Intracerebral hematoma volume was calculated using the 4/3 p abc formula [4] . 
Outcomes

Conclusion
• There is no approved reversal agent for factor Xa inhibitors.
• The effectiveness of PCC in major bleeding was assessed as Good in 66%, and Moderate in 17%.
• There was one (3%) thromboembolic event. 11 (31) 1 (3) 1 (3) 1 (3) 1 (3) 1 ( 
